3,​5,​6,​7,​8,​3',​4'-​Heptemthoxyflavone

3,5,6,7,8,3',4'-Heptemthoxyflavone, a flavonoid from satsuma peel, is an orally available CREB activator with anti-tumor and anti-neuroinflammatory activity. 3,5,6,7,8,3',4'-Heptemthoxyflavone inhibits collagenase activity and increases the content of type I procollagen in human dermal fibroblast neoblast (HDFn) cells. 3,5,6,7,8,3',4'-Heptemthoxyflavone induces brain-derived neurotrophic factor (BDNF) expression through the cAMP/ERK/CREB signaling pathway and reduces phosphodiesterase activity in C6 glioma^{[1][2][3][4][5]}. In Vitro:3,5,6,7,8,3',4'-Heptemthoxyflavone (HMF) (50-400 μg/mL; 24 h) does not affect neonatal human dermal fibroblasts at concentrations <200 μg/mL (HDFn) cell viability^[1].
3,5,6,7,8,3',4'-Heptemthoxyflavone (50-200 μg/mL; 24 h) significantly increases type I procollagen content of HDFn cells in a dose-dependent manner. and downregulates the expression of MMP-1, while upregulating the expression of type I procollagen in UV-induced HDFn cells^[1].
3,5,6,7,8,3',4'-Heptemthoxyflavone (HMF) (10 μM; 48 h) can activate ERK and cAMP response element binding protein (CREB), inhibit the activities of PDE4B and PDE4D, and increase cAMP levels in C6 glioma cell^[4].
In Vivo:3, 5, 6, 7, 8, 3', 4'- Heptemthoxyflavone (HPT) (0.025‰ w/v; po, in water; 2 weeks before tumor induction) inhibits NOR1/TPA-induced tumor promotion in mice^[2].
3, 5, 6, 7, 8, 3', 4'- Heptemthoxyflavone (HMF) (50 mg/kg, 100 mg/kg; po; once daily for 15 days) also exerts neuroprotective effects by enhancing the expression of BDNF in astrocyte in Corticosterone (HY-B1618)-induced depression-like mouse model^[5].